Sinotherapeutics Inc.

688247

CNE100005PL9

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
8.24 ^CNY	+1.60%		+3.52%	-24.95%

02/07	Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024.	CI
26/06	Sinotherapeutics Secures Regulatory Nod for Two Drugs	MT

Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024.

July 02, 2024

From April 1, 2024 to June 30, 2024, the company has repurchased 326,000 shares, representing 0.07% for CNY 2.69 million. With this, the company has completed the repurchase of 4,186,109 shares, representing 0.92% for CNY 35.01 million under the buyback announced on February 21, 2024.

Latest news about Sinotherapeutics Inc.

Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024.	02/07	CI
Sinotherapeutics Secures Regulatory Nod for Two Drugs	26/06	MT
Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024.	02/04	CI
Sinotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Sinotherapeutics Inc. announces an Equity Buyback for CNY 70 million worth of its shares.	21/02	CI
Sinotherapeutics Inc. authorizes a Buyback Plan.	19/02	CI
Sinotherapeutics Gets Nod for Mesalazine Tablets; Shares Drop 7%	05/02	MT
Sinotherapeutics Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Sinotherapeutics' Unit Gets Registration Certificate for Sevelamer Carbonate Tablets	26/23/26	MT
Sinotherapeutics Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Sinotherapeutics Inc.(SHSE:688247) added to Shanghai Stock Exchange A Share Index	25/23/25	CI
Sinotherapeutics Inc.(SHSE:688247) added to Shanghai Stock Exchange Composite Index	25/23/25	CI
Sinotherapeutics Gets US FDA Nod for Arthritis Drug	10/23/10	MT
Sinotherapeutics Signs Product Licensing Deal With US Drugmaker Lannett	07/23/07	MT
FDA Greenlights Sinotherapeutics' Mesalazine Enteric-Coated Tablets	17/23/17	MT
Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Sinotherapeutics Drug Selected in China's Centralized Drug Procurement	13/23/13	MT
Sinotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Sinotherapeutics’ Antifungal Drug Added to China’s Medical Insurance Catalog	19/23/19	MT
Sinotherapeutics Inc. has completed an IPO in the amount of CNY 424.8358 million.	22/22/22	CI

Chart Sinotherapeutics Inc.

Duration

Period

More charts

Company Profile

Sinotherapeutics Inc is China-based company mainly engaged in the research and development, commercial production and sales of pharmaceutical preparations. The Company's main businesses include research and development, production and sales of generic drugs, as well as contract research and development organization (CRO) services. The Company mainly operates in the domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SINOTHERAPEUTICS INC.	-24.95%	510M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+26.12%	45.33B
OTSUKA HOLDINGS CO., LTD.	+38.49%	25.36B
SANDOZ GROUP AG	+26.90%	16.7B
CIPLA LIMITED	+20.89%	14.59B
ZYDUS LIFESCIENCES LIMITED	+72.03%	14.26B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-10.35%	6.67B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	5.62B
STADA ARZNEIMITTEL	-8.87%	5.73B